866 related articles for article (PubMed ID: 15031492)
1. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
3. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Eck MJ; Manley PW
Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
[TBL] [Abstract][Full Text] [Related]
4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
5. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase inhibitors as a therapeutic modality.
Levitzki A
Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
[TBL] [Abstract][Full Text] [Related]
7. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
8. Novel protein kinases and molecular mechanisms of autoinhibition.
Cheetham GM
Curr Opin Struct Biol; 2004 Dec; 14(6):700-5. PubMed ID: 15582394
[TBL] [Abstract][Full Text] [Related]
9. Design strategies for protein kinase inhibitors.
Parang K; Sun G
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):617-29. PubMed ID: 15503864
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
Mol CD; Fabbro D; Hosfield DJ
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
[TBL] [Abstract][Full Text] [Related]
11. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
12. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
13. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
15. Targeting protein kinases in cancer therapy.
Fabbro D; García-Echeverría C
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):701-12. PubMed ID: 12630290
[TBL] [Abstract][Full Text] [Related]
16. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based design of a protein kinase inhibitor.
Parang K; Till JH; Ablooglu AJ; Kohanski RA; Hubbard SR; Cole PA
Nat Struct Biol; 2001 Jan; 8(1):37-41. PubMed ID: 11135668
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
[TBL] [Abstract][Full Text] [Related]
19. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
[TBL] [Abstract][Full Text] [Related]
20. Are MAP kinases drug targets? Yes, but difficult ones.
Margutti S; Laufer SA
ChemMedChem; 2007 Aug; 2(8):1116-40. PubMed ID: 17541990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
